Related Experiment Video
Updated: Feb 13, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Oncolytic viruses and immunity
Shyambabu Chaurasiya1, Nanhai G Chen2, Yuman Fong3
1Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Abstract:
Initially, direct oncolysis was thought to be the sole mechanism through which oncolytic viruses (OVs) exert their anti-tumor effect, and the immune system was perceived as the major obstacle in oncolytic virotherapy. Over the last decade, there has been a lot of debate on whether the immune system is a friend or foe of OVs. However, we are now at a stage where the initial thinking has been reversed as a result of compelling evidence that the immune system plays a critical role in the success of oncolytic virotherapy. In this review we discuss the importance of the involvement of innate and adaptive immunity for therapeutic efficacy of OVs, and the rational combination of OVs with other immunotherapies for further enhancement of overall therapeutic outcome.
Insights
Oncolytic viruses (OVs) initially faced challenges, but research now shows the immune system is crucial for their anti-tumor effects. Combining OVs with immunotherapy enhances treatment outcomes.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Early research viewed the immune system as an obstacle to oncolytic virus (OV) therapy.
- Recent evidence highlights the immune system's critical role in OV efficacy, reversing previous assumptions.
Purpose of the Study:
- To review the pivotal role of innate and adaptive immunity in oncolytic virotherapy.
- To explore rational combinations of OVs with other immunotherapies for improved therapeutic outcomes.
Main Methods:
- Literature review on the interplay between oncolytic viruses and the immune system.
- Analysis of current research on immune responses to OVs.
- Examination of combination strategies involving OVs and immunotherapy.
Main Results:
- The immune system is essential, not detrimental, to the success of oncolytic virotherapy.
- Both innate and adaptive immune responses significantly contribute to the anti-tumor effects of OVs.
- Combining OVs with other immunotherapies shows promise for enhanced treatment efficacy.
Conclusions:
- The immune system is a key facilitator of oncolytic virotherapy, shifting the paradigm from foe to friend.
- Harnessing immune responses alongside OV treatment is crucial for maximizing therapeutic potential.
- Strategic integration of OVs with immunotherapy offers a promising avenue for advancing cancer treatment.
Related Concept Videos
What are Viruses?
What is the Immune System?
Humoral Immune Responses
Introduction to Virus
Viruses of Archaea
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...

